AI-generated analysis. Always verify with the original filing.
ARS Pharmaceuticals, Inc. announced fourth quarter and full year 2025 financial results, reporting $28.1 million total revenue including $20.3 million U.S. neffy net product revenue and $72.2 million full year U.S. neffy net product revenue, with $245.0 million in cash supporting operations through cash-flow break-even. The company updated its corporate presentation and provided neffy commercialization and regulatory updates.
Event Type
Disclosure
Mandatory
Variant
8-K
of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange A
of this Current Report on Form 8-K, including Exhibit 99.2, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or othe
Financial Statements and Exhibits. (d) Exhibit Number Description 99.1 Press Release dated March 9, 2026 99.2 Company Presentation dated March 9, 2026 104 Cover
| Metric | Value | Basis |
|---|---|---|
| Total Revenue | $28.10 | |
| Net Product Revenue neffy U.S. | $20.30 | |
| Collaboration Revenue | $6.90 | |
| Supply Revenue | $0.90 | |
| Net Loss | $41.30 | |
| Net Loss per Share Basic and Diluted | $0.42 |